<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20190801062500Z</creation_date><modification_date>D:20210107131100Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-19-1392_h_dec_2.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 14.1.2021c(2021) 295 (final)</p></section><section><header>commission implementing decisionof 14.1.2021
 granting marketing authorisation under regulation (ec) no 726/2004 of the european 
 parliament and of the council for &quot;ervebo - ebola zaire vaccine (rvsv∆g-zebov-gp, 
 live)&quot;, a medicinal product for human use and repealing decision c(2019)8131(final)</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 14.1.2021
 granting marketing authorisation under regulation (ec) no 726/2004 of the european 
 parliament and of the council for &quot;ervebo - ebola zaire vaccine (rvsv∆g-zebov-
 gp, live)&quot;, a medicinal product for human use and repealing decision 
 c(2019)8131(final)</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, and in particular articles 10(2) and 14-a(8) thereof,having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof,
 having regard to the changes to the terms of the decision granting the marketing 
 authorisation requested by merck sharp &amp; dohme b.v. in accordance with regulation (ec) 
 no 1234/2008,
 having regard to the data submitted by merck sharp &amp; dohme b.v., on 21 august 2020,
 having regard to the opinion of the european medicines agency, formulated on 12 
 november 2020 by the committee for medicinal products for human use,
 whereas:
 (1)
 on 11 november 2019, authorisation for the placing on the market of &quot;ervebo - ebola 
 zaire 
 vaccine 
 (rvsv∆g-zebov-gp, 
 live)&quot; 
 was 
 granted 
 by 
 decision 
 c(2019)8131(final) subject to certain requirements, in accordance with article 14-a of 
 regulation (ec) no 726/2004 and regulation (ec) no 507/2006.
 (2)
 the specific obligations of the conditional marketing authorisation are fulfilled, in 
 view of the data submitted on 21 august 2020.
 (3)
 for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2019)8131(final) should therefore be replaced.
 1oj l 136, 30.4.2004, p. 1.2oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>(4)the medicinal product &quot;ervebo - ebola zaire vaccine (rvsv∆g-zebov-gp, live)&quot; 
 complies with the requirements set out in directive 2001/83/ec of the european 
 parliament and of the council of 6 november 2001 on the community code relating 
 to medicinal products for human use
 3.(5)
 it is therefore appropriate to replace the conditional marketing authorisation with a 
 marketing authorisation not subject to specific obligations.
 (6)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 has adopted this decision:
 article 1the marketing authorisation provided for in article 3 of regulation (ec) no 726/2004 is granted for the medicinal product &quot;ervebo - ebola zaire vaccine (rvsv∆g-zebov-gp, 
 live)&quot;, the characteristics of which are summarised in annex i to this decision. &quot;ervebo - 
 ebola zaire vaccine (rvsv∆g-zebov-gp, live)&quot; is registered in the union register of 
 medicinal products under number eu/1/19/1392.
 article 2the marketing authorisation concerning the medicinal product referred to in article 1 shall be subject to compliance with the conditions set out in annex ii and, in particular, with those 
 relating to manufacture and importation, control and issue.
 article 3the labelling and package leaflet concerning the medicinal product referred to in article 1 shall comply with the conditions set out in annex iii.
 article 4the placing on the market of &quot;ervebo - ebola zaire vaccine (rvsv∆g-zebov-gp, live)&quot; shall be subject to this decision from the date of its notification.
 the period of validity of the authorisation shall be five years from the date of notification of 
 this decision.
 article 5this decision repeals and replaces decision c(2019)8131(final) of 11 november 2019.3oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>article 6this decision is addressed to merck sharp &amp; dohme b.v., waarderweg 39, 2031 bn haarlem, nederland.
 done at brussels, 14.1.2021
 for the commissionsandra gallina
 director-general</p></section></body></xml>